Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Lader

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Current Psychiatry Reports|January 7, 2016
Withdrawing Benzodiazepines in Patients With Anxiety DisordersMalcolm Lader, Andri Kyriacou
CNS Drugs|December 10, 2008
Withdrawing benzodiazepines in primary careMalcolm Lader, Andre Tylee, John Donoghue
Depression and Anxiety|March 17, 2004
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorderPaolo Meoni, David Hackett, Malcolm Lader
Depression and Anxiety|July 27, 2004
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose studyMalcolm Lader, Karina Stender, Vera Bürger, et al.
The Annals of Pharmacotherapy|October 21, 2003
Causes and management of hyponatremiaBiff F Palmer, John R Gates, Malcolm Lader
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 15, 2005
Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensionsDan J Stein, Elisabeth Wreford Andersen, Malcolm Lader
Pharmacoepidemiology and Drug Safety|October 19, 2007
Mortality in schizophreniaPascal Auquier, Christophe Lançon, Frédéric Rouillon, et al.
The Primary Care Companion for CNS Disorders|December 2, 2011
Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysisKoen Demyttenaere, Elin Heldbo Reines, Sara Larsson Lönn, et al.
The International Journal of Neuropsychopharmacology|December 20, 2005
Discontinuation symptoms in depression and anxiety disordersDavid S Baldwin, Stuart A Montgomery, Rico Nil, et al.
Pharmacoepidemiology and Drug Safety|October 24, 2006
Mortality in schizophreniaPascal Auquier, Christophe Lançon, Frédéric Rouillon, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Current Psychiatry Reports|January 7, 2016
Withdrawing Benzodiazepines in Patients With Anxiety DisordersMalcolm Lader, Andri Kyriacou
CNS Drugs|December 10, 2008
Withdrawing benzodiazepines in primary careMalcolm Lader, Andre Tylee, John Donoghue
Depression and Anxiety|March 17, 2004
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorderPaolo Meoni, David Hackett, Malcolm Lader
Depression and Anxiety|July 27, 2004
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose studyMalcolm Lader, Karina Stender, Vera Bürger, et al.
The Annals of Pharmacotherapy|October 21, 2003
Causes and management of hyponatremiaBiff F Palmer, John R Gates, Malcolm Lader
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 15, 2005
Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensionsDan J Stein, Elisabeth Wreford Andersen, Malcolm Lader
Pharmacoepidemiology and Drug Safety|October 19, 2007
Mortality in schizophreniaPascal Auquier, Christophe Lançon, Frédéric Rouillon, et al.
The Primary Care Companion for CNS Disorders|December 2, 2011
Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysisKoen Demyttenaere, Elin Heldbo Reines, Sara Larsson Lönn, et al.
The International Journal of Neuropsychopharmacology|December 20, 2005
Discontinuation symptoms in depression and anxiety disordersDavid S Baldwin, Stuart A Montgomery, Rico Nil, et al.
Pharmacoepidemiology and Drug Safety|October 24, 2006
Mortality in schizophreniaPascal Auquier, Christophe Lançon, Frédéric Rouillon, et al.
Pageof 3